摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2'-(7,7'-biimidazo[1,2-b][1,2,4]triazine-3,3'-diyl)dipropan-2-ol

中文名称
——
中文别名
——
英文名称
2,2'-(7,7'-biimidazo[1,2-b][1,2,4]triazine-3,3'-diyl)dipropan-2-ol
英文别名
2-[7-[3-(2-Hydroxypropan-2-yl)imidazo[1,2-b][1,2,4]triazin-7-yl]imidazo[1,2-b][1,2,4]triazin-3-yl]propan-2-ol
2,2'-(7,7'-biimidazo[1,2-b][1,2,4]triazine-3,3'-diyl)dipropan-2-ol化学式
CAS
——
化学式
C16H18N8O2
mdl
——
分子量
354.371
InChiKey
DJSBGEWUVRAEKD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.4
  • 重原子数:
    26
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    127
  • 氢给体数:
    2
  • 氢受体数:
    8

反应信息

  • 作为产物:
    描述:
    3-羟基-3-甲基-2-丁酮 在 palladium diacetate airpotassium acetate 作用下, 以 甲醇异丁醇N,N-二甲基乙酰胺 为溶剂, 反应 62.0h, 生成 2,2'-(7,7'-biimidazo[1,2-b][1,2,4]triazine-3,3'-diyl)dipropan-2-ol
    参考文献:
    名称:
    咪唑并[1,2- b ] [1,2,4]三嗪的钯催化区域选择性芳基化:α2 / 3-选择性GABA激动剂的合成
    摘要:
    聚合,实用,高效地合成2',6-二氟-5'-[3-(1-羟基-1-甲基乙基)咪唑并[1,2- b ] [1,2,4]三嗪-7-基]联苯-2-甲腈(1),一种口服活性的GABA甲α 2/ 3 -选择性激动剂,进行说明。七步无色谱合成已在多千克规模上得到证明,并利用了联芳基溴6和咪唑三嗪22作为关键中间体。经由高选择性芳族溴化反应制备联芳基溴化物6。氨基三嗪15与氯乙醛的区域选择性缩合提供了所需的咪唑三嗪中间体22。在最后一步中,具有高度区域选择性的钯催化的芳基化作用突出了该路线的效率。
    DOI:
    10.1021/jo0507035
点击查看最新优质反应信息

文献信息

  • Palladium-Catalyzed Regioselective Arylation of Imidazo[1,2-<i>b</i>][1,2,4]triazine:  Synthesis of an α<sub>2/</sub><sub>3</sub>-Selective GABA Agonist
    作者:Donald R. Gauthier,、John Limanto、Paul N. Devine、Richard A. Desmond、Ronald H. Szumigala、Bruce S. Foster、R. P. Volante
    DOI:10.1021/jo0507035
    日期:2005.7.1
    A convergent, practical, and efficient synthesis of 2‘,6-difluoro-5‘-[3-(1-hydroxy-1-methylethyl)imidazo[1,2-b][1,2,4]triazin-7-yl]biphenyl-2-carbonitrile (1), an orally active GABAA α2/3-selective agonist, is described. The seven-step, chromatography-free synthesis was demonstrated on a multi-kilogram scale and utilized biaryl bromide 6 and imidazotriazine 22 as key intermediates. Biaryl bromide 6
    聚合,实用,高效地合成2',6-二氟-5'-[3-(1-羟基-1-甲基乙基)咪唑并[1,2- b ] [1,2,4]三嗪-7-基]联苯-2-甲腈(1),一种口服活性的GABA甲α 2/ 3 -选择性激动剂,进行说明。七步无色谱合成已在多千克规模上得到证明,并利用了联芳基溴6和咪唑三嗪22作为关键中间体。经由高选择性芳族溴化反应制备联芳基溴化物6。氨基三嗪15与氯乙醛的区域选择性缩合提供了所需的咪唑三嗪中间体22。在最后一步中,具有高度区域选择性的钯催化的芳基化作用突出了该路线的效率。
查看更多

同类化合物

咪唑并[1,2-b][1,2,4]三唑并[4,3-D][1,2,4]三嗪 3-甲基咪唑并[1,2-b][1,2,4]噻嗪 3-溴-7-甲基咪唑并[1,2-b][1,2,4]三嗪 3-(三氟甲基)咪唑并[1,2-b][1,2,4]三嗪 2-咪唑并[1,2-B][1,2,4]三嗪-7-丙烷-2-醇 2-(3-溴咪唑并[1,2-b][1,2,4]-7-三嗪)丙烷-2-醇 3-(3-methylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine 2-imidazo[1,2-b][1,2,4]triazin-3-ylpropan-2-ol hydrochloride 2,2'-(7,7'-biimidazo[1,2-b][1,2,4]triazine-3,3'-diyl)dipropan-2-ol 2-(2,4-difluorophenyl)-6-((pyridin-2-yloxy)methyl)imidazo[1,2-b][1,2,4]triazine 2-(4-fluorophenyl)-7-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,2-b]-[1,2,4]-triazine 7-Bromo-2-methylimidazo[1,2-b][1,2,4]triazine 1,2,3,4-tetrahydro-dibenzo[4,5:e]imidazo[1,2-b][1,2,4]triazine 2-(7-bromo-imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol imidazo[1,2-b][1,2,4]triazine-6-carboxylic acid ethyl ester 2-(imidazo[1,2-b][1,2,4]triazin-6-yl)ethanol 2-(4-fluorophenyl)-7-(4-methoxybenzyl)imidazo[1,2-b][1,2,4]triazine 7,9-Dimethylimidazo[1,2-b][1,2,4]benzotriazine 7-Methylimidazo[1,2-b][1,2,4]benzotriazine 7-Methoxyimidazo[1,2-b][1,2,4]benzotriazine imidazo[1,2-b][1,2,4]triazine-6-carbaldehyde 3-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-b][1,2,4]triazin-7-amine 7-nitro-3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine Imidazo[1,2-b][1,2,4]triazin-2(1H)-one 6-(3-Methoxycyclohexyl)-2-phenylimidazo[1,2-b][1,2,4]triazine 3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine 2,3-diphenyl-6-thiophen-2-yl-imidazo[1,2-b][1,2,4]triazine 7-(2-chloropyridin-4-yl)-3-trifluoromethylimidazo[1,2-b][1,2,4]triazine 3-(1-fluoro-1-methylethyl)imidazo[1,2-b][1,2,4]triazine 7-[(3,4-dihydroxyphenyl)methylidene]-3-methyl-2-methylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one 6-(5-Chlorothiophen-2-yl)-2,3-dimethylimidazo[1,2-b][1,2,4]triazine 6-(5-Bromothiophen-2-yl)-2,3-dipyridin-2-ylimidazo[1,2-b][1,2,4]triazine 7-[(3,4-dihydroxyphenyl)methylidene]-3-ethyl-2-ethylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one 2-(5-{7-[2-(difluoromethoxy)benzyl]-6-methylimidazo[1,2-b][1,2,4]triazin-2-yl}-pyrimidin-2-yl)propan-2-ol 2-[2-Chloro-4-[2-[2-cyclopentyl-5-(imidazo[1,2-b][1,2,4]triazin-6-ylmethyl)-4,6-dioxooxan-2-yl]ethyl]phenyl]-2-methylpropanenitrile (7E)-3-methyl-2-methylidene-7-[(2,3,4-trimethoxyphenyl)methylidene]-1H-imidazo[1,2-b][1,2,4]triazin-6-one (3E)-3-[(2-chloro-6-fluorophenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (3Z)-3-[(3-methoxyphenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12Z)-12-[(2,4-dichlorophenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (12E)-12-[(4-chlorophenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (3E)-3-(thiophen-2-ylmethylidene)-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12E)-12-[[4-(dimethylamino)phenyl]methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (7E)-7-[(2-methoxyphenyl)methylidene]-3-methyl-2-methylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one (3E)-3-[(3,4-dihydroxyphenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12E)-12-[(3,4,5-trimethoxyphenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (12E)-12-[(2-methoxyphenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one 2-(Azepan-1-yl)-3-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-b][1,2,4]triazine 4-[(11-Hydroxy-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,7,9,11-tetraen-12-yl)methylidene]-2-methoxycyclohexa-2,5-dien-1-one 2-(1-Adamantyl)-6,7,8,9-tetrahydroimidazo[1,2-b][1,2,4]benzotriazine 6-[1-(Furan-2-ylmethyl)-2,5-dimethylpyrrol-3-yl]-2,3-diphenylimidazo[1,2-b][1,2,4]triazine